What is TherapeuticsMD Price-to-Operating-Cash-Flow?
As of today (2024-05-14), TherapeuticsMD's share price is $2.04.
TherapeuticsMD's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.24. Hence, TherapeuticsMD's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for TherapeuticsMD's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 13 years, TherapeuticsMD's highest Price-to-Operating-Cash-Flow Ratio was 21.07. The lowest was 0.86. And the median was 2.52.
TherapeuticsMD's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.45.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.24.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of TherapeuticsMD was -321.30% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 57.60% per year.
During the past 13 years, TherapeuticsMD's highest 3-Year average Operating Cash Flow per Share Growth Rate was 74.50% per year. The lowest was -56.40% per year. And the median was 8.90% per year.
TherapeuticsMD Price-to-Operating-Cash-Flow Historical Data
The historical data trend for TherapeuticsMD's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TherapeuticsMD Price-to-Operating-Cash-Flow Chart
|
TherapeuticsMD Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
5.60 |
- |
|
TherapeuticsMD Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
5.60 |
2.60 |
1.18 |
3.01 |
- |
Competitive Comparison of TherapeuticsMD's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TherapeuticsMD's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where TherapeuticsMD's Price-to-Operating-Cash-Flow falls into.
TherapeuticsMD Price-to-Operating-Cash-Flow Calculation
TherapeuticsMD's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 2.04 | / | -2.236 |
| = | |
TherapeuticsMD's Share Price of today is $2.04.
TherapeuticsMD's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.24.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
TherapeuticsMD (TherapeuticsMD) Business Description
Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Executives
| Marlan D Walker |
officer: General Counsel |
951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431 |
| Joseph Ziegler |
officer: Principal Financial Officer |
1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062 |
| Michael C Donegan |
officer: CAO and VP of Finance |
6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507 |
| Rubric Capital Management Lp |
10 percent owner |
155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
| Brian Bernick |
director |
951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487 |
| Gail K Naughton |
director |
C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
| Mark A Glickman |
officer: Chief Business Officer |
C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
| Justin Hunter Roberts |
director |
C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
| Tommy G Thompson |
director |
7711 CARONDELET, ST. LOUIS MO 63105 |
| Karen Ling |
director |
C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
| Paul Bisaro |
director |
|
| Angus C. Russell |
director |
C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Jules A. Musing |
director |
9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
| David Efraim Rosen |
10 percent owner |
155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
| Collins Cooper C. |
director |
33219 FOREST WEST DRIVE, MAGNOLIA TX 77354 |
TherapeuticsMD (TherapeuticsMD) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TXMD has been successfully added to your